Helping Patients Find the Cancer Treatment Resources They Deserve

How can we help kidney cancer patients?

Massive Bio offers an independent cancer treatment analysis as well as free clinical trial matching for kidney cancer patients. Our patient advocates work closely with patients to gather information on their current medical status, and then will provide a list of options from available renal cancer clinical trials close to your home.

We can also provide a second opinion through our Virtual Tumor Board from cancer specialists. The Virtual Tumor Board (VTB) is comprised of highly specialized oncologists from nationally-recognized Cancer Centers of Excellence. In just 7-10 days after receiving your medical records, we can get you a treatment plan without having to travel far distances and use your valuable time.

Clinical Trials

There are approximately 1,780 clinical trials for kidney cancer that are currently recruiting patients in the United States. With such an extensive list, many of them could be beneficial for you. Our team of oncology nurses and our artificial intelligence based clinical trial matching system will find the best option for you.

A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)


Five-year survival rate for kidney (renal)patients is 75%. It is the 8th most common cancer type among new cases for 2019. Renal cancer is more common in men than women. American Indian/Alaska Natives are the most susceptible group by far for kidney cancer. Their number of deaths more than doubles the national average. However, their total number of cases is equal to the average for all males.


Some risk factors for Kidney Cancer include smoking, obesity, high blood pressure, and family history. Genetic testing can be done for those who have or had relatives with kidney cancer to determine if you have a higher risk of developing cancer. Diseases such as von Hippel-Lindau (VHL) syndrome can also put patients at risk of kidney cancer.


Common treatment methods for Kidney (Renal) Cancer:

  • Active surveillance
  • Surgery (Includes radical nephrectomy, partial nephrectomy, and Laparoscopic surgery)
  • Radiofrequency ablation
  • Cryoablation
  • Targeted therapy
  • Immunotherapy
  • Chemotherapy

Learn Your Kidney Cancer Clinical Trial and Treatment Options

By submitting, you agree to our Terms And Conditions and have read and acknowledged our Privacy Statement.


There is no uniform method for screening patients for Kidney Cancer. Imaging tests are often used by doctors to look at the kidney and surrounding areas to look for tumors. These imaging tests usually consist of a CT scan, MRI scan, or an Ultrasound. Other forms of screening for Kidney Cancer include biopsies and an angiography, which uses dye and an x-ray to spot anything abnormal. Complete blood count (CBC) and blood chemistry tests can reveal signs of Kidney Cancer based on red blood cell count and calcium levels.


The number of Kidney Cancer cases have increased dramatically since the year 1975. There were 7.1 per 100,000 people in the United States with Kidney Cancer. Today, that number has more than doubled to 15.4 cases per 100,000 people. Despite the dramatic rise in the number of cases, the amount of deaths has remained identical to its number in 1975. This means that great strides have been made in the treatment options for Kidney Cancer patients, but prevention of the disease remains ineffective.


  • Renal cell carcinoma
  • Urothelial carcinoma
  • Sarcoma (Rare)
  • Wilms tumor (Most common in pediatric cases)
  • Lymphoma


Our team of patient advocates can help guide you to treatment options you might not have been previously aware of. Although you might be new to cancer, we certainly are not. Navigating cancer patients through the tricky path of finding the best treatment is our goal. No two cancer patients are alike, which is why we find treatment for all of our patients based on their specific genomics, location, stage of cancer, and nearly 100 more data points.